

EDITH proof-of-concept infrastructure

Outline of the session

- Presentation of application and related technical implementation
- User perspectives are used to guide presentation
 - researchers
 - communities
 - industry
 - clinicians
 - patients

Researchers

Caroline Roney or Laura Bevis, Elisa Rauseo, Queen Mary University of London


Cardiovascular Use Case: Personalised Models for Atrial Fibrillation

Dr Laura Bevis, Postdoctoral Research Associate (l.bevis@qmul.ac.uk)

Personalised Cardiac Modelling Lab (PCM Lab), Dr Caroline Roney (UKRI Future Leaders Fellow)
School of Engineering and Materials Science, Digital Environment Research Institute, QMUL



Who we are...



Dr Caroline Roney

UKRI Future Leaders Fellow
Reader in Computational Medicine

Mathematics, Biomedical Engineering,
Computational Modelling



Dr Elisa Rauseo

Cardiologist with special interest in
Cardiovascular imaging and AI

Queen Mary University of London,
Barts Health NHS Trust



Dr Laura Bevis

Postdoctoral Research Associate in
Cardiac Digital Twins

Mathematician - Fluid
Dynamics, Biological Modelling



Prof Greg Slabaugh

Professor of Computer Vision and AI
Director of the Digital Environment
Research Institute (DERI)

Personalized Cardiac Modelling Lab, School of Engineering and Materials Science, Queen Mary University of London




Digital Environment Research Institute, Queen Mary University of London

Plus clinical collaborators at Barts NHS Trust

Who we are...

QMUL Cardiovascular Use Case


- Personalised simulations for atrial fibrillation
 - **Inputs:** Patient specific anatomy from CT, MRI or electroanatomical mapping (EAM) data
 - **Outputs:** Patterns of electrical activity that indicate targets for personalised AF treatment
- Clinical collaboration to ensure relevance



Motivation for Atrial Fibrillation Modelling

Atrial Fibrillation

- Most prevalent sustained arrhythmia in US & UK
- AF leads to diminished quality of life, heart failure, morbidity
- AF associated with increased risk of stroke



Narayan, S. M. et al.. Atrial fibrillation. *The Lancet*, 1997.


Long-term success rate from persistent AF reaches ~21% after conventional methods of treatment.

Brooks et al., Outcomes of long-standing persistent atrial fibrillation ablation: a systematic review, Heart Rhythm, 2015.


Motivation for Atrial Fibrillation Modelling

Atrial Fibrillation

- Most prevalent sustained arrhythmia in US & UK
- AF leads to diminished quality of life, heart failure, morbidity
- AF associated with increased risk of stroke




**Coordinated activity
over atria (No AF)**




Migrating wavelets of re-entrant activation (AF)


Narayan, S. M. et al.. Atrial fibrillation. *The Lancet*, 1997.




Imaging data



Biophysical modelling



Personalised therapy selection




**Patient-specific
digital twins**


*R. Karim et al, Acutus medical initiates ce mark study for focal pulsed field ablation therapy to treat atrial fibrillation. (2020)

Personalised Computational Medicine

- Data explosion
- Virtual trials
- Personalised treatments?




Model Pipeline



Roney, C.H. *et al.* (2023), Constructing bilayer and volumetric atrial models at scale. *Interface focus*, 13(6), p.20230038.

Model Pipeline

In silico model for assessing individual responses to irregular heart rhythm treatments



Carlos Edgar Lopez Barrera, Winning Early Career entry Archer2 Image and Video Competition 2023



Ecosystem
for Digital Twins
in Healthcare

<https://www.archer2.ac.uk/about/gallery/2023-image-comp/>



Queen Mary
University of London


Modelling for Atrial Fibrillation




Applications of cardiovascular use case

- Mechanistic investigation: change e.g. fibres, fibrosis, etc. in patient-specific models
- Investigate effects on electrophysiology, fibrillatory dynamics & treatment outcomes
- Developing optimal patient-specific treatments
- Large in silico trials
- Machine learning for longer term predictions on clinical timescales

Model generation:



Pipeline:



LA Segmentation

RA Segmentation



Semhar Misghina: "Batrial Modelling for In Silico Prediction of Atrial Fibrillation Inducibility", CinC 2023

Roney C et al. Constructing a Human Atrial Fibre Atlas. Ann Biomed Eng. 2020.





Ecosystem
for Digital Twins
in Healthcare




Queen Mary
University of London

Calibrating electrical properties:



D

Total number of rotational activity per LA segment at different pacing rates across all cases



Caterina Vidal Horrach


Caterina Vidal Horrach & Dr Shohreh Honarbakhsh: "Patient-specific Atrial Fibrillation Simulation Prediction Depend on Rhythm Used for Calibration", CinC 2023

Calibrating electrical properties:

B Models

1 Local Activation Time (LAT)


CS 250ms pacing rate CS 600ms




C Models

1 Bipolar Voltage (BV) map


CS 250ms pacing rate CS 600ms




A. EGM AF Omnipolar maps




B. EGM AF Bipolar maps




C. LGE fibrosis distributions



D. EGM SR Omnipolar maps




E. EGM SR Bipolar maps




Total number of rotational activity per LA segment at different pacing rates across all cases


Calibrated to LAT maps



Calibrated to BV maps








Caterina Vidal Horrach




Dr Mahmoud Ehresh

Ablation approaches and anti-arrhythmic drug therapies:



Ovais Jaffery

Ablation approaches and anti-arrhythmic drug therapies:




Semhar Misghina



Ovais Jaffery

Large virtual cohort modelling:


AF terminates with I A ablation for low RA fibrosis




Dr Alexander Zolotarev: "Atrial Fibrosis Distribution Generation based on the Diffusion Model", CinC 2023

Large virtual cohort modelling:

AF terminates with LA ablation for low RA fibrosis








LGE



PVI + LA LGE ablation




PVI + biatrial LGE ablation



*AF sustains with LA ablation,
and terminates with biatrial ablation for high RA fibrosis*

Comparing ablation approaches in a virtual cohort of 4000 patients, constructed using 4 fibrosis distributions applied to 1000 atrial anatomies from a statistical shape model



Combining patient-specific modelling and population data...:



Roney CH et al.
Predicting Atrial Fibrillation Recurrence by Combining Population Data and Virtual Cohorts of Patient-Specific Left Atrial Models. Circulation Arrhythmia & Electrophysiology (2022)



...and using deep learning to predict outcomes:




Dr Alexander Zolotarev
Predicting Atrial Fibrillation Treatment
Outcome with Siamese Multi-modal
Fusion and Digital Twins, MIDL 2024

In-silico ventricular tachycardia therapy:



Dr Fuyu Cheng



Coming soon: **ventricularmtk**

Cardiovascular use case: github pipeline

- Pipeline for constructing personalised models for atrial fibrillation (AF) to be integrated into proof-of-concept repository & platform for the VHT
- Source code, examples, instructions, computational & user requirements
- Open source: <https://github.com/pcmlab/atrialmtk/>


 Open Access
 Check for updates
 View PDF
Tools Share
Cite this article

Research articles

Constructing bilayer and volumetric atrial models at scale

Caroline H. Roney✉, Jose Alonso Solis Lemus, Carlos Lopez Barrera, Alexander Zolotarev, Onur Ulgen, Eric Kerfoot, Laura Bevis, Semhar Misghina, Caterina Vidal Horrach, Ovais A. Jaffery, Mahmoud Ehresh, ... [See all authors](#)

Published: 15 December 2023 | <https://doi.org/10.1098/rsfs.2023.0038>





Roney, C.H., et al. (2023), Constructing bilayer and volumetric atrial models at scale. *Interface focus*, 13(6), p.20230038

Cardiovascular use case: workflows

Workflow 1:

This workflow takes a segmentation mask as input, which can be produced from input directly by the user if already provided. The steps to run these examples are:



- 0 ImagingData
- 1 Clipping
- 2 Landmarks
- 3 Processing
- 4 Simulation



Workflow 2:

This workflow applies where the user is provided with the surface file rather than the imaging data. Since it starts from atrial surface data, it does not include the 0 ImagingData or 1 Clipping steps from workflow 1 and we instead start with the following mesh:

- 0 SurfaceMeshData
- 2 Landmarks
- 3 Processing
- 4 Simulation





Cardiovascular use case: workflows

Workflow 1:

This workflow takes a segmentation mask as input, which can be produced from input directly by the user if already provided. The steps to run these examples are:



- 0ImagingData
- 1Clipping
- 2Landmarks
- 3Processing
- 4Simulation




Workflow 2:

This workflow applies where the user is provided with the surface file rather than the imaging data. It starts with atrial surface data and vessels, it does not include the 0ImagingData or 1Clipping steps from workflow 1 and we instead start with the following mesh:


- 0SurfaceMeshData
- 2Landmarks
- 3Processing
- 4Simulation



Cardiovascular use case: data flow




Cardiovascular use case: data flow




Cardiovascular use case

Integration in VHT systems

- Integrating different biophysical models: electrophysiology, mechanics, fluids
- Integrating across spatial scales: from cellular changes to organ level changes
- Multi-organ: brain – heart interactions
- Infrastructure requirements




Integration in VHT systems in the clinic



Delivering care across North-East London

- Turnover - approx. £2bn
- Capital programmes - approx. £60m/year
- Workforce - 24k people



Interested??

INTERFACE FOCUS

royalsocietypublishing.org/journal/rsfs

Research



Cite this article: Roney CH *et al.* 2023
Constructing bilayer and volumetric
atrial models at scale. *Interface Focus* **13**:
20230038.

Constructing bilayer and volumetric atrial models at scale

Caroline H. Roney^{1,2}, Jose Alonso Solis Lemus^{2,3}, Carlos Lopez Barrera^{1,4},
Alexander Zolotarev¹, Onur Ulgen², Eric Kerfoot², Laura Bevis¹,
Semhar Misghina¹, Caterina Vidal Horrach¹, Ovais A. Jaffery¹,
Mahmoud Ehresh¹, Cristobal Roderio^{2,3}, Dhani Dharmapran⁵,
Gonzalo R. Ríos-Muñoz^{6,7,8}, Anand Ganesan⁵, Wilson W. Good⁹, Aurel Neic¹⁰,
Gernot Plank^{11,12}, Luuk H. G. A. Hopman¹³, Marco J. W. Götte¹³,
Shohreh Honarbakhsh¹⁴, Sanjiv M. Narayan¹⁵, Edward Vigmond^{16,17} and
Steven Niederer^{2,3,18}

atrialmtk Public

Edit Pins Watch 2 Fork 1 Star 3

main 1 Branch 2 Tags

Go to file

Add file Code

About

Atrial Modelling Toolkit

- Readme
- GPL-3.0 license
- Activity
- Custom properties
- 3 stars
- 2 watching
- 1 fork

Report repository

Releases 2

atrialmtk for Interface Focus on Nov 15, 2023 Latest

+ 1 release

Commit History

Author	Message	Time	Commits
caroroney	Update README.md	26271f7 · 6 months ago	120 Commits
	Examples Added figures	9 months ago	
	images Delete images/_svc.png	8 months ago	
	src Delete src/3Processing/_ct-2-bilayer.sh	8 months ago	
	LICENSE Create LICENSE	9 months ago	
	README.md Update README.md	6 months ago	

atrialmtk

README GPL-3.0 license



Cardiovascular use case: 100 open-source patient-specific models



Ecosystem
for Digital Twins
in Healthcare



Cardiovascular use open pat mod



https://zenodo.org/record/5801337



zenodo

Search



Upload

Communities

Log in

Sign up

January 31, 2022

Dataset

Open Access

Predicting atrial fibrillation recurrence by combining population data and virtual cohorts of patient-specific left atrial models

Roney, Caroline; Sim, Iain; Yu, Jin; Beach, Marianne; Mehta, Arihant; Solis-Lemus, Jose; Kotadia, Irum; Whitaker, John; Corrado, Cesare; Razeghi, Orod; Vigmond, Edward; Narayan, Sanjiv; O'Neill, Mark; Williams, Steven; Niederer, Steven

Abstract

Background: Current ablation therapy for atrial fibrillation is sub-optimal and long-term response is challenging to predict. Clinical trials identify bedside properties that provide only modest prediction of long-term response in populations, while patient-specific models in small cohorts primarily explain acute response to ablation. We aimed to predict long-term atrial fibrillation recurrence after ablation in large cohorts, by using machine learning to complement biophysical simulations by encoding more inter-individual variability.

Methods: Patient-specific models were constructed for 100 atrial fibrillation patients (43 paroxysmal, 41 persistent, 16 long-standing persistent), undergoing first ablation. Patients were followed for 1-year using ambulatory ECG monitoring. Each patient-specific biophysical model combined differing fibrosis patterns, fibre orientation maps, electrical properties and ablation patterns to capture uncertainty in atrial properties and to test the ability of the tissue to sustain fibrillation. These simulation stress tests of different model variants were post-processed to calculate atrial fibrillation simulation metrics. Machine learning classifiers were trained to predict atrial fibrillation recurrence using features from the patient history, imaging and atrial fibrillation simulation metrics.

Results: We performed 1100 atrial fibrillation ablation simulations across 100 patient-specific models. Models based on simulation stress tests alone showed a maximum accuracy of 0.63 for predicting long-term fibrillation recurrence. Classifiers trained to history, imaging and simulation stress tests (average ten-fold cross-validation area under the curve 0.85 ± 0.09 , recall 0.80 ± 0.13 , precision 0.74 ± 0.13) outperformed those trained to history and imaging (area under the curve 0.66 ± 0.17), or history alone (area under the curve 0.61 ± 0.14).

Conclusion: A novel computational pipeline accurately predicted long-term atrial fibrillation recurrence in individual patients by combining outcome data with patient-specific acute simulation response. This technique could help to personalise selection for atrial fibrillation ablation.

Dataset Description: We include surface meshes in vtk format, consisting of the nodes, triangular elements, the atrial

1,378

views

2,297

downloads

[See more details...](#)

Indexed in

OpenAIRE

Publication date:

January 31, 2022

DOI:

DOI 10.5281/zenodo.5801337


Grants:

[Research Councils UK:](#)

- Predicting Atrial Fibrillation Mechanisms Through Deep Learning (MR/S015086/1)
- Personalised Model Based Optimal Lead Guidance in Cardiac Resynchronisation Therapy (EP/M012492/1)
- Wellcome EPSRC Centre for Medical Engineering (NS/A000049/1)
- Uncertainty Quantification in Prospective and Predictive Patient Specific Cardiac Models (EP/P01268X/1)

Thank you

Dr Laura Bevis: l.bevis@qmul.ac.uk
PCM Lab: <https://pcmlab.co.uk/contact-us/>



Acknowledgements


NIHR | Barts Biomedical
Research Centre

NHS
Barts Health
NHS Trust

 **Queen Mary**
University of London



Caterina Vidal Horrach
Ovais Jafri
Semhar Misghina
Felix Cheng
Alexander Zolotarev
Mahmoud Ehresh
Laura Bevis
Elisa Rauseo
Carlos Lopez Barrera




Future
Leaders
Fellowships

Video showing steps for generating atrial models,
Archer2 image competition winner, Carlos Lopez Barrera

Acknowledgements

Queen Mary / Barts

Sherry Honarbakhsh
Steffen Petersen
Patsy Munroe
Musa Abdulkareem
Aaron Mark Lee
Vijaya Kanthasamy
Malcolm Finlay
Richard Schilling
Ross Hunter
Nikhil Ahluwalia
Thomas Iskratsch
Anthony Mathur
Greg Slabaugh



KCL

Marianne Beach
Giulia Raffaele
Rokas Bendikas
Arihant Mehta
Jess Yu
José Solis Lemus
Orod Razeghi
John Whitaker
Iain Sim
Irum Kotadia
Bradley Porter
Nick Child
Mark O'Neill
Martin Bishop
Steven Williams
Jas Gill



Brompton

Shouvik Haldar
Haseeb Valli

Acutus Medical

Wilson Good
Lea Melki



UQ, Sheffield, Leeds

Sam Coveney
Richard Clayton
Richard Wilkinson
Jeremy Oakley



Imperial College

Steve Niederer
Cristobal Rodero
Fu Siong Ng
Nicholas Peters

Graz

Gernot Plank
Matthias Gsell
Karli Gillette
Aurel Neic



Stanford

Sanjiv Narayan
AJ Rogers

Liryc

Edward Vigmond
Jason Bayer
Hubert Cochet
Pierre Jais
Marianna Meo
Remi Dubois
Yingjing Feng



Researchers

Sofia Karvounari, Konstantinos Triantos , ATHENA research center

Researchers



EDITH (DEV)

Register

User type **Researcher**
Clinician
Patient
Industry

First name

Last name

Email

Username

Password


Confirm password

[« Back to Login](#)

EDITH is a coordination and support action funded by the Digital Europe program of the European Commission under grant agreement n° 101083771



Creating an account...



The screenshot shows a web interface for the EDITH (DEV) system. At the top, it says "EDITH (DEV)". Below this is a "Register" form. The form has a "User type" dropdown menu set to "Researcher". The form fields are: "First name", "Last name", "Email", "Username", "Password", and "Confirm password". At the bottom of the form, there is a link "< Back to Login" and a blue "Register" button.


- Data Access and Utilization:
 - Accessing Comprehensive Data Sets
 - Cross-Referencing Data: researchers can cross-reference information, identify correlations
- Data Acquisition and Management Tools:
 - Databases and Data Warehouses: For storing and managing large volumes of medical, genetic, and behavioral data.
 - Data Integration Tools: For integrating data from various sources such as clinical records, genomic data, and wearable devices.
 - Data Security and Privacy Tools: To ensure that sensitive health data is protected and compliant with regulations like GDPR and HIPAA.
 - Data transformation services: data/input/output mapping services for a given standard



Working with CWL

The screenshot displays the CWL interface with a green header bar. On the left is a logo of a head with a brain. In the center is a search bar labeled "Search records..." with a red magnifying glass icon. To the right of the search bar are links for "Use cases" and "My dashboard". On the far right is a "Log in" button with a user icon. Below the header, there are two tabs: "Basic search" (selected) and "Advanced search". The "Basic search" tab contains a "Title" input field, a "Description" text area, and a "Search" button. Below the search form, there are three metrics: "New records", "New users", and "Files size".

Creating DOI



The screenshot displays the DataCite Fabrica EDITH interface. At the top, the DataCite Fabrica logo is on the left, and navigation links for 'About', 'Support', and 'REMB.EDITH' are on the right. Below the logo, the 'EDITH' title is followed by a horizontal menu with 'Info', 'Settings', 'Prefixes', and 'DOIs'. The 'Info' tab is active, showing a 'Create DOI' button with a checkmark icon. To the right, the role is set to 'Repository'. A bar chart titled 'DOIs by year' shows a single bar for the year 2024 with a value of 5. The x-axis is labeled with '2014' and '2024'. The bottom of the page features four columns of links: 'About Us' (What we do, Governance, Steering and Working Groups, Team, Job Opportunities, Projects), 'Work With Us' (Create DOIs, Integrate Workflows, Enable Discovery, Promote Reuse, Strategic Initiatives), 'Membership' (Become a Member, DataCite Fee Model, Membership Enquiry, DataCite Members), and 'Contact us' (Privacy Policy, Terms and Conditions, Imprint). A 'Resources' section lists 'Metadata Schema' and 'DataCite Members'. A status indicator shows 'All Systems Operational'. A 'FEEDBACK' button is in the bottom right corner.

DataCite Fabrica

EDITH

Info Settings Prefixes DOIs

Create DOI

Role: Repository

DOIs by year

5 in 2024

2014 2024

About Us

- What we do
- Governance
- Steering and Working Groups
- Team
- Job Opportunities
- Projects

Work With Us

- Create DOIs
- Integrate Workflows
- Enable Discovery
- Promote Reuse
- Strategic Initiatives

Membership

- Become a Member
- DataCite Fee Model
- Membership Enquiry
- DataCite Members

Contact us

- Privacy Policy
- Terms and Conditions
- Imprint


Resources

- Metadata Schema
- DataCite Members

All Systems Operational

FEEDBACK

Collaborative Research



Sharing Models and Data: Collaborate with other researchers by sharing virtual models, data, and findings



Standardizing Research: Use standardized models and data



Version Control Systems: To manage code and data changes (e.g., Git, GitHub).



Collaboration Platforms (e.g., Jupyter Notebooks, Workflows engine).




Modeling and Simulation: Running Simulations
Personalized Simulation




Improved UX

- Visualization Tools:
 - Data Visualization Tools: To create interactive charts and graphs
 - 3D Visualization Software: For rendering and interacting with complex anatomical and physiological models
- Access to High-Performance Computing (HPC) Systems



Communities

Martin Golebiewski, Heidelberg Institute for Theoretical Studies



Integrative Data Management Systems: e.g. FAIRDOM SEEK

Wolstencroft K, Krebs O, Snoep JL, Stanford NJ, Bacall F, Golebiewski M, Kuzyakiv R, Nguyen Q, Owen S, Soiland-Reyes S, Straszewski J, van Niekerk DD, Williams AR, Malmström L, Rinn B, Müller W, Goble C: **FAIRDOMHub: a repository and collaboration environment for sharing systems biology research.** *Nucleic Acids Research* 45(D1): D404-D407 (2017). DOI: 10.1093/nar/gkw1032

Wolstencroft K, Owen S, Krebs O, Nguyen Q, Stanford NJ, Golebiewski M, Weidemann A, Bittkowski M, An L, Shockley D, Snoep JL, Mueller W, Goble C:
SEEK: a systems biology data and model management platform. *BMC Systems Biology*, 9: 33 (2015).
DOI: 10.1186/s12918-015-0174-y

Communities

Sofia Karvounari, ATHENA research center

Required Adaptations

```
1. {
2.   "$schema": "http://json-schema.org/draft-07/schema#",
3.   "additionalProperties": false,
4.   "id": "local://records/record_model_extended.json",
5.   "properties": {
6.     "$schema": {
7.       "$ref": "local://definitions-v1.0.0.json#/schema"
8.     },
9.     "metadata": {
10.      "description": "Model extended metadata.",
11.      "type": "object",
12.      "properties": {
13.        "age": {
14.          "description": "Represents the age of the subject when the data were collected.",
15.          "type": "integer"
16.        },
17.        "body": {
18.          "description": "Represents the type of transformation the body has undergone, if any.",
19.          "type": "string"
20.        },
21.        "credibility": {
22.          "description": "Credibility rating for the model.",
23.          "type": "integer"
24.        },
25.        "geolocation": {
26.          "description": "Geographical location relevant to this record.",
27.          "type": "string"
28.        },
29.        "ontology": {
30.          "description": "The ontology the model is based on.",
31.          "type": "string"
32.        },
33.        "scale": {
34.          "description": "The part of the body the model refers to.",
35.          "type": "string"
36.        },
37.        "standard": {
38.          "description": "The model standard, if applicable.",
39.          "type": "string"
40.        }
41.      },
42.      "type": "object"
43.    },
44.    "title": "EDITH Record Model Schema",
45.    "type": "object"
46.  }
47. }
48. }
```

```
1. {
2.   "$schema": "http://json-schema.org/draft-07/schema#",
3.   "id": "local://records/record_model_extended.json",
4.   "properties": {
5.     "$schema": {
6.       "$ref": "local://definitions-v1.0.0.json#/schema"
7.     },
8.     "metadata": {
9.      "description": "Model extended metadata.",
10.      "properties": {
11.        "age": {
12.          "description": "Represents the age of the subject when the data were collected.",
13.          "type": "integer"
14.        },
15.        "body": {
16.          "description": "Represents the type of transformation the body has undergone, if any.",
17.          "type": "string"
18.        },
19.        "clustering": {
20.          "description": "The clustering index for the model.",
21.          "type": "number"
22.        },
23.        "credibility": {
24.          "description": "Credibility rating for the model.",
25.          "type": "integer"
26.        },
27.        "execution environment": {
28.          "description": "Recommended execution environment for executing the model.",
29.          "type": "string"
30.        },
31.        "geolocation": {
32.          "description": "Geographical location relevant to this record.",
33.          "type": "string"
34.        },
35.        "model file link": {
36.          "description": "Link to the model file.",
37.          "format": "uri",
38.          "type": "string"
39.        },
40.        "model format": {
41.          "description": "The model format, if applicable.",
42.          "type": "string"
43.        },
44.        "model licence": {
45.          "description": "The licence for the model.",
46.          "type": "string"
47.        },
48.        "model type": {
49.          "description": "The type of the model.",
50.          "type": "string"
51.        },
52.        "ontology": {
53.          "description": "The ontology the model is based on.",
54.          "type": "string"
55.        },
56.        "paper references": {
57.          "description": "References to papers describing the model, e.g. Pubmed-ID or doi",
58.          "type": "array"
59.        },
60.        "parameter file link": {
61.          "description": "Link to the parameter file",
62.          "format": "uri",
63.          "type": "string"
64.        },
65.        "scale": {
66.          "description": "The part of the body the model refers to.",
67.          "type": "string"
68.        },
69.        "seek instance": {
70.          "description": "The SEEK instance, where the model is stored.",
71.          "type": "string"
72.        },
73.        "standard": {
74.          "description": "The model standard, if applicable.",
75.          "type": "string"
76.        },
77.        "webpage": {
78.          "description": "Link to webpage describing the model.",
79.          "type": "object"
80.        }
81.      },
82.      "type": "object"
83.    },
84.    "title": "EDITH Record Model Schema",
85.    "type": "object"
86.  }
87. }
88. }
```

before



after

Enhanced Data Privacy and Security:

- Decentralized Data Storage: data remains within the local environment of each participating entity
- Data Sovereignty: Institutions retain control over their data, ensuring compliance with local regulations and policies

Enhanced Data Diversity and Quality:

- Aggregation of Diverse Datasets: integration of data from various sources, resulting in a richer and more diverse dataset
- Minimization of Bias: mitigate biases from localized data sets.

Interoperability and Standardization:

- Common Standards and Protocols
- Best Practices Sharing

Benefits

Scalability and Resource Optimization:

- Distributed Computing Resources: computational power and storage capacity of all participating nodes
- Cost Efficiency: distributed maintenance and infrastructure costs

Accelerated Research and Innovation:

- Collaborative Research: sharing insights and findings while maintaining control over their local data
- Faster Validation and Replication: innovations quickly validated and replicated

Benefits



Enhanced Personalization and Precision

Localized Adaptation: VHT models can be tailored to reflect the specific characteristics and needs

Real-Time Data Updates: Localized data continuously updated



Compliance with Ethical and Regulatory Standards

Local Ethical Oversight: compliance with local ethical guidelines and regulatory requirements

Regulatory Compliance: easy adaptation to various national and international regulations

Benefits



Resilience and Redundancy

System Redundancy: the failure of one node does not compromise the entire infrastructure
Disaster Recovery: Data and tasks can be redistributed



Community and Stakeholder Engagement

Stakeholder Involvement: More active role for local communities and stakeholders



Innovation and Customization

Tailored Solutions developed by the different nodes

Industry

Mariano Vázquez, ELEM

VIRTUAL HUMAN TWINS: THE FUTURE OF MEDICINE **NOW**

SUPERCOMPUTER-BASED VIRTUAL HUMANS

MARIANO VÁZQUEZ
ELEM BIOTECH

ELEM
THE VIRTUAL
HUMANS FACTORY

A SPINOFF
COMPANY



A VIRTUAL HUMAN'S PLATFORM

SUPERCOMPUTING **EFFICIENCY**
+
ACCURATE MULTISCALE / MULTIPHYSICS **MODELLING**
+
VIRTUAL **POPULATION** GENERATION

SUPERCOMPUTER BASED **IN-SILICO CLINICAL TRIALS**
TO OPTIMIZE AND **PERSONALIZE** MEDICAL THERAPIES

A VIRTUAL HUMAN'S PLATFORM




CLOUD DEPLOYED
(HYBRID: BACKEND + HPC INSTANCES)

ACCESSED THROUGH A WEB APP
TO SETUP THE CASE AND ANALYZE THE RESULTS

SECURED ACCESS

IN-SILICO CLINICAL TRIALS

A CLINICAL TRIAL




CLINICAL
CONCLUSION




IN-SILICO CLINICAL TRIALS



IN-SILICO CLINICAL TRIALS



IN-SILICO CLINICAL TRIALS



PRECISION MEDICINE

A PATIENT



CLINICAL
CONCLUSION



PRECISION MEDICINE

A PATIENT



HIS/HER DATA



BIOMARKERS'
ANALYSIS



CLINICAL
CONCLUSION



PRECISION MEDICINE

A PATIENT



HIS/HER DATA



BIOMARKERS'
ANALYSIS



CLINICAL
CONCLUSION



HIS/HER VIRTUAL
HUMAN



COMPUTATIONAL
BIOMARKERS'
ANALYSIS



EG:
MIOCARDIAL WORK
DISTRIBUTION



THE CARDIOVASCULAR SYSTEM

COLLABORATORS:

THE VISIBLE HEART LAB - UNIV. OF MINNESOTA (US)
CENTRO NACIONAL DE INVESTIGACION CARDIOVASCULAR (SPAIN)
HOSPITAL DE SANT PAU (SPAIN)
UNIVERSITY OF OXFORD (UK)
UNIVERSITAT POMPEU FABRA (SPAIN)
UNIVERSITAT POLITECNICA DE VALENCIA (SPAIN)
GEORGE MASON UNIVERSITY (US)
UNIVERSITY COLLEGE LONDON (UK)
SAN DIEGO STATE UNIVERSITY (US)
MEDTRONIC (US)
BOEHRINGER INGELHEIM (D)
FDA (US)

THE VIRTUAL HEART ANATOMY & PHYSIOLOGY

HH097

HH125

HH165

HH168

HH197

HH229

HH248

HH140

HH157

HH212

HH311

HH317

HH075

HH076

HH077

HH085


HH089

HH092

PATIENTS DATABASE

FEMALE, MALE, CHILDREN

WITH THE VHL, UNIV. OF MINNESOTA












THE VIRTUAL HEART ANATOMY & PHYSIOLOGY

VIRTUAL
PATIENTS DATABASE
FEMALE, MALE, CHILDREN
HEALTH, DISEASE &
TREATMENT

Cardiac modelling



25-years old female healthy volunteer



Cardiac Trials, Virtual Populations, High Performance Computing


A screenshot of a login form. It features three input fields stacked vertically. The first field is labeled 'Email' and contains the text 'example@gmail.com'. The second field is labeled 'Password' and contains a series of dots representing a masked password. The third field is a red button with the text 'Login' in white. The form is set against a dark gray background.

HUMAN CARDIAC **IN-SILICO** CLINICAL TRIAL PIPELINE FOR CARDIAC SAFETY ASSESSMENT



VIRTUAL CLINICAL QT EXPOSURE-RESPONSE STUDIES – A TRANSLATIONAL COMPUTATIONAL APPROACH
AGUADO-SIERRA ET AL.
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS,
2024

CRT ASSESSMENT THROUGH PERSONALIZATION



CONCLUSION

ELEM BIOTECH IS THE VIRTUAL HUMANS FACTORY

THE FUTURE NOW

THANKS!

VIRTUAL HUMAN TWINS: THE FUTURE OF MEDICINE NOW

MARIANO VÁZQUEZ
CSO/CTO - ELEM BIOTECH
TEAM LEADER - BARCELONA
SUPERCOMPUTING CENTER

CONTACT: MARIANO@ELEM.BIO

A SPINOFF
COMPANY



ELEM

THE VIRTUAL HUMANS
FACTORY

European
Innovation
Council



Industry

Evita Mailli, ATHENA research center

Industry

EDITH (DEV)

Register

User type

First name

Last name

Email

Username

Password

Confirm password

[« Back to Login](#)

How



Data Anonymization and Aggregation

Anonymized Data

Aggregated Data (e.g. statistical analyses, trends, and summaries derived from their data)



Data Access Controls, Usage Policies

Controlled Access: different user roles - only authorized users can access specific datasets

Usage Policies: can restrict certain uses



Federated Learning

Federated Learning: data remains within the company's infrastructure, insights and models are shared

How

Partnerships and Licensing Agreements

- Licensing Models: grant access while retaining ownership and control
- Data Sharing Agreements: how data can be accessed, used, and shared

License / Rights *

License / Rights ▼

Creative Commons
Attribution 4.0
International

Subjects

Contribution of Tools and Algorithms

- Proprietary Algorithms: used within the repository without revealing the underlying data or methodology (e.g., providing APIs)
- Open-Source Tools: Develop and share open-source tools, software, and algorithms

Benefit-Sharing Models

- Reciprocal Sharing: Implement benefit-sharing models where contributors receive access to other valuable data and tools in return for their contributions.
- Incentive Programs: reward companies for contributing valuable data and resources (e.g., access to exclusive research findings, recognition, financial incentives)


What

- Patient Data and Demographics
- Disease Models:
 - Disease Progression: Simulations of how different diseases progress over time in various demographic groups.
 - Pathophysiology: underlying mechanisms of diseases and how they affect different body systems.
- Pharmacokinetics and Pharmacodynamics:
 - Drug Interactions: how different drugs interact within the human body
 - Dosage Simulations: Models predicting the effects of different drug dosages on patients with varying characteristics.

What

- Clinical trial design
- Behavioral and Lifestyle Data:
 - Lifestyle Impact: Simulations showing how factors like diet, exercise, and smoking affect health outcomes.
 - Behavioral Health: Data on how mental health conditions and behavioral patterns influence physical health.
- Public Health Data:
 - Epidemiological Models: Simulations of disease spread and the impact of public health interventions.
 - Health Impact Assessments: Data assessing the potential health impacts of policy changes or environmental factors.

Use case oriented



Healthcare provider

Vincent Uyttendaele, InSiliCare and University of Liège

Clinical Use Case

Glucose Control in Intensive Care

Vincent Uyttendaele
Insilicare | University of Liège
vincent@insilicare.com

Glucose Control (GC) in the Intensive Care unit (ICU)

Hyperglycaemia occurs in 30-50% of ICU patients (with or without diabetes)

Hyperglycaemia increases risk of infection, morbidities, and death


Normoglycaemia is associated with improved outcomes and reduced mortality

Hypoglycaemia lead to severe brain damage and death




Glucose Control (GC) in the Intensive Care unit (ICU)

Insulin must be administered but **increases the risk of hypoglycaemia**




Glucose Control (GC) in the Intensive Care unit (ICU)

What makes GC hard is variability: **differ between patient & over time**




Glucose Control (GC) in the Intensive Care unit (ICU)

Permissive hyperglycaemia as a “**first do no harm**” approach



A Digital Twin Model of Glucose & Insulin dynamics to identify 'variability'





“White Box” model characterising pharmacodynamics and kinetics of glucose and insulin metabolic pathways

3 clinical inputs : Glucose, Insulin, Nutrition over time

Other inputs such as : diabete, age, sex, BMI

1 output : **Insulin sensitivity** (not / hardly measurable)


A Digital Twin Model of Glucose & Insulin dynamics to identify 'variability' in clinics



Patient-specific **insulin sensitivity** profile can be identified



Application 1




Clinicians and Academics can use the model for individual / cohort analyses or in-silico trials

For example, safety assessment of new protocol design **prior clinical use**



Application 2



Clinical application:
use the model associated with **predictive AI** to personalise treatment by **assessing and balancing treatment risks** in real-time for clinical decision support at patient bedside




Gains



Optimal GC and Nutrition improving safety and efficacy
→ Happy patients with improved outcomes



High protocol compliance, reduced clinical burden, and reduced human errors → Happy clinical staff



Improved patient management across nursing shifts and wards → Happy co-workers / streamline process



>5000€/patient reduction costs ! → Happy social security!

Thank you for the attention!



www.edith-csa.eu



@EDITH_CSA_EU



@EDITH_CSA



insilicare

Save lives with confidence



EDITH is a coordination and support action funded by the Digital Europe program of the European Commission under grant agreement n° 101083771



Healthcare provider

Amaryllis Raouzaïou, Konstantinos Triantos, ATHENA research center

Healthcare provider Clinician

EDITH (DEV)

Register

User type

First name

Last name

Email

Username

Password

Confirm password

[« Back to Login](#)

Criteria



Integration with Health IT Systems

EHR Integration: integration with EHR systems to allow easy access to patient data and insights.

Interoperability: compatibility with various health IT systems to facilitate smooth data exchange and integration.



User-Friendly Interfaces

Clinician Dashboards: intuitive interfaces for easy access to VHT insights and recommendations.



Data Security and Privacy

Compliance: with all relevant data protection regulations to maintain patient confidentiality.



Training and Support

Clinician Training Programs
Ongoing Support

Services



Personalized Patient Care

Individualized Treatment Plans and Predictive Analytics using precise virtual models.



Clinical Decision Support - Therapeutic Adjustments

Real-Time Data Integration with electronic health records (EHRs) to provide real-time insights (future work)

Advanced Imaging Interpretation

Dynamic Treatment Adjustment: test different therapeutic interventions virtually, adjusting treatments dynamically based on simulated outcomes.



Interdisciplinary Collaboration

Team-Based Care
Specialist Consultation



Monitoring and Follow-Up

Dynamic Monitoring: new patient data, monitor disease progression and treatment effectiveness

Remote Monitoring: telemedicine



Services



Modeling and Simulation

Running Simulations: Use the repository to run simulations on virtual human models to predict outcomes of medical treatments, understand disease progression, or evaluate surgical procedures without risking patient safety.

Personalized Simulations: Utilize individual-specific data from the repository to create personalized virtual human twins for precise medical research and customized treatment planning.



Research and Clinical Trials

Trial Outcomes: Results from previous clinical trials, including efficacy and safety data for various treatments.

Patient Recruitment: Information on patient populations that participated in trials, helping to design future studies.




Training and Education

Clinician Training: rare or complex cases

Continuing Medical Education: latest medical advancements and techniques.

Running a Workflow



Patient

Sabato Mellone, University of Bologna
Amaryllis Raouzaïou, ATHENA research center

Patient

EDITH (DEV)

Register

User type

First name

Last name

Email

Username

Password

Confirm password

[« Back to Login](#)

Process

Registration and Access:

- Create an Account: separate "Patient" role
- Consent and Permissions: informed consent, outlining what data will be shared, how it will be used, and who will have access to it.

Privacy and Security


- *Only authorized personnel and the patient can view or use the data.*
- *Compliance with relevant data protection regulations*

Data Upload Methods:


- Manual Entry: medical history, current medications, lifestyle information.
- Device Integration: Sync data from wearable devices
- Electronic Health Records (EHR) Integration: health records and lab results.

Different Data Types:


- Vital Signs, Biometric Data, Laboratory Results, Lifestyle Data, Symptom Tracking etc.



Use case: risk of fracture



Use case: risk of fracture



Benefits

Personalized Health Insights

- Tailored Recommendations
- Predictive Analytics

Personal Health Record Maintenance

Enhanced Disease Management

- Chronic Condition Monitoring (e.g., diabetes, hypertension, asthma)
- Medication Management (symptoms and side effects)

Improved Communication with Healthcare Providers

- Data Sharing
- Remote Consultation

User Friendly Visualisations and Statistics

Participate in Research

- Clinical Trials: Easily participate in clinical trials by providing relevant health data
- Crowdsourced Health Studies: Contribute anonymized data to larger health studies